Cargando…

Biodistribution and radiation dosimetry of [(18)F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer

AIM: We investigated the whole-body distribution and the radiation dosimetry of [(18)F]-JK-PSMA-7, a novel (18)F-labeled PSMA-ligand for PET/CT imaging of prostate cancer. METHODS: Ten patients with prostate cancer and biochemical recurrence or radiologic evidence of metastatic diseases were examine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hohberg, Melanie, Kobe, Carsten, Krapf, Philipp, Täger, Philipp, Hammes, Jochen, Dietlein, Felix, Zlatopolskiy, Boris D., Endepols, Heike, Wild, Markus, Neubauer, Stephan, Heidenreich, Axel, Neumaier, Bernd, Drzezga, Alexander, Dietlein, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658635/ https://www.ncbi.nlm.nih.gov/pubmed/31346821 http://dx.doi.org/10.1186/s13550-019-0540-7

Ejemplares similares

[(18)F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer
por: Dietlein, Felix, et al.
Publicado: (2020)

Uptake in non-affected bone tissue does not differ between [(18)F]-DCFPyL and [(68)Ga]-HBED-CC PSMA PET/CT
por: Hammes, Jochen, et al.
Publicado: (2018)

Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
por: Dietlein, Markus, et al.
Publicado: (2015)

Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer
por: Vázquez, Sergio Muñoz, et al.
Publicado: (2021)

Threshold for defining PSMA-positivity prior to (177)Lu-PSMA therapy: a comparison of [(68)Ga]Ga-PSMA-11 and [(18)F]F-DCFPyL in metastatic prostate cancer
por: Heilinger, Jan, et al.
Publicado: (2023)

Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseases
por: Hammes, Jochen, et al.
Publicado: (2018)

Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents
por: Endepols, Heike, et al.
Publicado: (2019)

Assessment of the In Vivo Relationship Between Cerebral Hypometabolism, Tau Deposition, TSPO Expression, and Synaptic Density in a Tauopathy Mouse Model: a Multi-tracer PET Study
por: Endepols, Heike, et al.
Publicado: (2022)

(68)Ga-DOTA-DiPSMA PET/CT Imaging: Biodistribution, Dosimetry, and Preliminary Application in Prostate Cancer
por: Zhang, Jiaying, et al.
Publicado: (2022)

Preclinical biodistribution and dosimetry and human biodistribution comparing (18)F-rhPSMA-7 and single isomer (18)F-rhPSMA-7.3
por: Knorr, Karina, et al.
Publicado: (2022)

F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
por: Giesel, Frederik L., et al.
Publicado: (2016)

(177)Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry
por: Abouzayed, Ayman, et al.
Publicado: (2023)

Mediastinal goiter diagnosed by functional imaging
por: Michels, Guido, et al.
Publicado: (2012)

Prostate specific membrane antigen (PSMA) and Prostate Cancer Staging: is our current conventional staging obsolete?
por: Céspedes, Melissa Segura, et al.
Publicado: (2021)

Biodistribution and internal radiation dosimetry of a companion diagnostic radiopharmaceutical, [(68)Ga]PSMA-11, in subcutaneous prostate cancer xenograft model mice
por: Kim, Su Bin, et al.
Publicado: (2021)

Biokinetics and dosimetry of (18)F‐PSMA‐1007 in patients with prostate cancer
por: Hvittfeldt, Erland, et al.
Publicado: (2022)

A Practical Method for the Preparation of (18)F-Labeled Aromatic Amino Acids from Nucleophilic [(18)F]Fluoride and Stannyl Precursors for Electrophilic Radiohalogenation
por: Zarrad, Fadi, et al.
Publicado: (2017)

Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry
por: Kabasakal, Levent, et al.
Publicado: (2017)

In vivo Molecular Imaging of Glutamate Carboxypeptidase II Expression in Re-endothelialisation after Percutaneous Balloon Denudation in a Rat Model
por: Endepols, Heike, et al.
Publicado: (2018)

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
por: Plichta, Kristin A., et al.
Publicado: (2021)

Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors
por: Ngen, Ethel J., et al.
Publicado: (2021)

Safety, Biodistribution, and Radiation Dosimetry of (18)F-rhPSMA-7.3 in Healthy Adult Volunteers
por: Tolvanen, Tuula, et al.
Publicado: (2021)

Evaluation of 3-l- and 3-d-[(18)F]Fluorophenylalanines as PET Tracers for Tumor Imaging
por: Krämer, Felicia, et al.
Publicado: (2021)

Relative Efficacy of (225)Ac-PSMA-617 and (177)Lu-PSMA-617 in Prostate Cancer Based on Subcellular Dosimetry
por: Lee, Hwan
Publicado: (2022)

Characterization of SnO(2)-based (68)Ge/(68)Ga generators and (68)Ga-DOTATATE preparations: radionuclide purity, radiochemical yield and long-term constancy
por: Sudbrock, Ferdinand, et al.
Publicado: (2014)

Radiation dosimetry of [(68)Ga]PSMA-11 in low-risk prostate cancer patients
por: Sandgren, Kristina, et al.
Publicado: (2019)

Evaluation of Radiation dosimetry of (99m)Tc-HYNIC-PSMA and imaging in prostate cancer
por: Zhang, Jianping, et al.
Publicado: (2020)

Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging
por: Topoozian, Mark, et al.
Publicado: (2023)

Expression of Prostate Specific Membrane Antigen (PSMA) in Breast Cancer
por: Unger, Clara, et al.
Publicado: (2022)

Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [(177)Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer
por: Stangl-Kremser, Judith, et al.
Publicado: (2021)

The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging
por: Eder, Ann-Christin, et al.
Publicado: (2021)

Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of (225)Ac-PSMA (Prostate-Specific Membrane Antigen)
por: Belli, Maria Luisa, et al.
Publicado: (2020)

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
por: Wang, Hui, et al.
Publicado: (2023)

JK
por: Marwaha, Seema
Publicado: (2021)

Streamlined Schemes for Dosimetry of (177)Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer
por: Kurth, Jens, et al.
Publicado: (2021)

Biodistribution and dosimetry for combined [(177)Lu]Lu-PSMA-I&T/[(225)Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
por: Delker, Astrid, et al.
Publicado: (2023)

(18)F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study
por: Vierasu, Irina, et al.
Publicado: (2023)

Author Correction: Evaluation of Radiation dosimetry of (99m)Tc-HYNIC-PSMA and imaging in prostate cancer
por: Zhang, Jianping, et al.
Publicado: (2020)

Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort
por: Zschäbitz, Stefanie, et al.
Publicado: (2022)

The oncological characteristics of non‐prostate‐specific membrane antigen (PSMA)‐expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography
por: Veerman, Hans, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9ncaga1rrgu3rvfvcdctftbsph